Transparency Market Research Circulating Tumor Cells (CTCs) Prognostic Technologies Market in 2014 – 2020: Transparency Market Research
Single User License:
USD 4595 Multi User License:
USD 7595 Corporate User License:
USD 10595 100 Page Report
Published Date 26-June-2014 Buy Now
Request Sample
Press Release
Circulating Tumor Cells (CTCs) Prognostic Technologies Market Expected to Reach USD 2.16 Billion Globally in 2020
Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
REPORT DESCRIPTION According to a new market report published by Transparency Market Research Circulating Circulating Tumor Cells (CTCs) Prognostic Technologies Market and Applications: Prostate Cancer, Breast Cancer, Colorectal Cancer and Others] - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020, the global circulating tumor cells (CTCs) prognostic technologies market was valued at USD 0.43 billion in 2013 and is expected to grow at a CAGR of 26.3% from 2014 to 2020, to reach an estimated value of USD 2.16 billion in 2020. Browse the Circulating Tumor Cells Prognostic Technologies Market Research Report with complete TOC http://www.transparencymarketresearch.com/ctcs-prognostic-technologiesmarket.html Circulating tumor cells (CTCs) are specialized rare cells, that have detached from the primary tumors of the body and disseminated in the vasculature system of the body, eventually causing metastasis. CTCs are composed of particular cells that act as seeds for successive development of additional metastatic tumors in essential distant organs, which is liable for the majority of cancer-related deaths. CTCs are not easily detected since these cells are present in less numbers in the blood stream. Therefore, detection of CTCs during the progression of the tumor provides a prognostic value of the tumor progression as well as evaluates the efficacy of therapeutic intervention. According to the UICC (Union for International Cancer Control), over the next two decades, globally cancer cases will increase by nearly 75%, reaching almost to 25 million. Additionally, according to the ACS (American Cancer Society), it has been projected that in 2014, approximately 1,665,540 people would be diagnosed with cancer and around 585,720 people would die due to cancer, in the U.S. alone. This escalating base of cancer cases would need next generation prognostic technologies as well as targeted therapeutics for effective diagnosis and treatment of the disease, which would alternatively increase the demand for modern age CTCs prognostic technologies. Get Free Sample Report at http://www.transparencymarketresearch.com/sample/sample.php? flag=S&rep_id=2497 The circulating tumor cells (CTCs) prognostic technologies market has been primarily segmented in terms of technology and applications. The technology market further comprises tumor cell enrichment and tumor cell detection. Moreover, the tumor cell enrichment market is further segmented into filtration, centrifugation and immunomagnetic methods; among which, immunomagnetic methods accounted for the largest market due to widespread commercial availability and high effectiveness. Moreover, the CTCs detection market is further bifurcated into molecular methods and optical methods, among which, the optical methods segment is expected to foresee a remarkable growth rate of over 27.3% from 2014 to 2020. Furthermore, the application segment of this market consists of major application areas such as prostate cancer, breast cancer, colorectal cancer and others (lung cancer, ovarian cancer and pancreatic cancer). Among the various applications of CTCs prognostic technologies, breast cancer and prostate cancer is expected to witness the fastest growth (27.1% & 25.2% respectively) during the forecast period owing to the high incidence and prevalence rate of these cancers and high adoption rate for CTCs technologies for therapeutic monitoring. However, it is also expected that colorectal cancer as well as
other types of cancer will account for an admirable share of the market (24.2 % and 15% respectively in 2013) due to their rising prevalence rate and increasing research and development activities for discovering targeted therapeutics. It is expected that by the year 2020, the market value of CTCs prognostic technologies for application in prostate shall be worth more than USD 684.0 million. Browse all Medical Devices Market Research Reports @ http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html In terms of geography, North America accounted for the largest CTCs prognostic technologies market in the year 2013 (over 50%) followed by Europe. However, Asia Pacific is estimated to exhibit the fastest growth rate owing to the expected rise in various types of cancer coupled with high research and development initiatives and growing adoption rate for advanced prognostic technologies. This market is highly consolidated in nature characterized by few players occupying approximately 70% of the overall market share. The major players of this market include Epic Sciences, Inc., Fluxion Biosciences, Inc., Silicon Biosystems, S.p.A., Rarecells USA, Inc. and Veridex, LLC
TABLE OF CONTENT Chapter 1 Introduction 1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology
Chapter 2 Executive Summary 2.1 Market Snapshot: Global CTCs Prognostic Technologies Market 2.2 Comparative Analysis: Global CTCs Prognostic Technologies Market, by Geography, 2013 & 2020 (Value %)
Chapter 3 Global CTCs Prognostic Technologies Market Overview 3.1 Market Dynamics and Overview 3.1 Market Drivers 3.1.1 Escalating Prevalence Rate of Cancer
3.1.2 High Cost-benefit Ratio 3.1.3 Increased Evaluation of Therapeutic Monitoring 3.1.4 Technological Development 3.2 Market Restraints 3.2.1 High Pricing Associated with CTCs Detection 3.2.2 Lack of Specificity and Sensitivity 3.2.3 Reluctance in Adopting Advanced Prognostic Technologies 3.3 Market Opportunities 3.3.1 Strengthening Distribution Network In Emerging Markets 3.3.2 Development of Personalized Medicines based on CTCs
Browse the Circulating Tumor Cells Prognostic Technologies Market Research Report with complete TOC http://www.transparencymarketresearch.com/ctcs-prognostic-technologiesmarket.html 3.4 Porter’s Five Forces Analysis 3.4.1 Bargaining Power of Suppliers 3.4.2 Bargaining Power of Buyers 3.4.3 Threat of Substitutes 3.4.4 Threat of New Entrants 3.4.5 Competitive Rivalry 3.5 Event Impact Analysis (Historical Trends and Future Outlook), 2012 – 2020 3.6 Market Attractiveness Analysis of Global CTCs Prognostic Technologies Market, by Geography 3.7 Competitive Landscape 3.7.1 Global Market Share Analysis, by Key Players, Global CTCs Prognostic Technologies Market, 2013 (Value %)
Chapter 4 Global CTCs Prognostic Technologies Market, by Technology 4.1 Overview 4.2 Tumor Cell Enrichment 4.2.1 Global Tumor Cell Enrichment Market Revenue, 2012 – 2020 (USD Million) 4.2.2 Filtration 4.2.2.1 Global Tumor Cell Enrichment by Filtration Market Revenue, 2012 – 2020 (USD Million) 4.2.3 Centrifugation 4.2.3.1 Global Tumor Cell Enrichment by Centrifugation Market Revenue, 2012 – 2020 (USD Million) 4.2.4 Immunological and Immunomagnetic Methods 4.2.4.1 Global Tumor Cell Enrichment by Immunological and Immunomagnetic Methods Market Revenue, 2012 – 2020 (USD Million) 4.3 Tumor Cell Detection 4.3.1 Global Tumor Cell Detection Market Revenue, 2012 – 2020 (USD Million) 4.3.2 Molecular Methods 4.3.2.1 Global Tumor Cell Detection by Molecular Methods Market Revenue, 2012 – 2020 (USD Million) 4.3.3 Optical Methods 4.3.3.1 Global Tumor Cell Detection by Optical Methods Market Revenue, 2012 – 2020 (USD Million)
Chapter 5 Global CTCs Prognostic Technologies Market, by Applications 5.1 Overview
5.1.1 Global CTCs Prognostic Technologies Market Revenue, by Applications, 2012 – 2020 (USD Million) 5.2 Prostate Cancer 5.2.1 Global CTCs Application in Prostate Cancer Market Revenue, 2012 – 2020 (USD Million) 5.3 Breast Cancer 5.3.1 Global CTCs Application in Breast Cancer Market Revenue, 2012 – 2020 (USD Million) 5.4 Colorectal Cancer 5.4.1 Global CTCs Application in Colorectal Cancer Market Revenue, 2012 – 2020 (USD Million) 5.5 Others (Lung Cancer, Ovarian Cancer and Pancreatic Cancer) 5.5.1 Global CTCs Application in Other Cancer Types Market Revenue, 2012 – 2020 (USD Million)
Browse the Circulating Tumor Cells Prognostic Technologies Market Research Report with complete TOC http://www.transparencymarketresearch.com/ctcs-prognostic-technologiesmarket.html
Chapter 6 Global CTCs Prognostic Technologies Market, by Geography 6.1 Overview 6.1.1 Global CTCs Prognostic Technologies Market Revenue, by Geography, 2012 – 2020 (USD Million) 6.2 North America 6.2.1 North America CTCs Prognostic Technologies Market Revenue, 2012 – 2020 (USD Million) 6.3 Europe 6.3.1 Europe CTCs Prognostic Technologies Market Revenue, 2012 – 2020 (USD Million) 6.4 Asia-Pacific 6.4.1 Asia-Pacific CTCs Prognostic Technologies Market Revenue, 2012 – 2020 (USD Million)
6.5 Rest of the World (RoW) 6.5.1 RoW CTCs Prognostic Technologies Market Revenue, 2012 – 2020 (USD Million)
Chapter 7 Recommendations
Chapter 8 Company Profiles 8.1 AdnaGen GmbH 8.1.1 Company Overview 8.1.2 Financial Overview 8.1.3 Product Portfolio 8.1.4 Business Strategies 8.1.5 Recent Developments 8.2 Advanced Cell Diagnostics, Inc. 8.2.1 Company Overview 8.2.2 Financial Overview 8.2.3 Product Portfolio 8.2.4 Business Strategies 8.2.5 Recent Developments 8.3 AVIVA Biosciences Corporation 8.3.1 Company Overview 8.3.2 Financial Overview 8.3.3 Product Portfolio 8.3.4 Business Strategies
8.4 Celula, Inc. 8.4.1 Company Overview 8.4.2 Financial Overview 8.4.3 Product Portfolio 8.4.4 Business Strategies
Browse the Circulating Tumor Cells Prognostic Technologies Market Research Report with complete TOC http://www.transparencymarketresearch.com/ctcs-prognostic-technologiesmarket.html
8.5 Epic Sciences, Inc. 8.5.1 Company Overview 8.5.2 Financial Overview 8.5.3 Product Portfolio 8.5.4 Business Strategies 8.5.5 Recent Developments 8.6 Fluxion Biosciences, Inc. 8.6.1 Company Overview 8.6.2 Financial Overview 8.6.3 Product Portfolio 8.6.4 Business Strategies 8.6.5 Recent Developments 8.7 Rarecells USA, Inc. 8.7.1 Company Overview
8.7.2 Financial Overview 8.7.3 Product Portfolio 8.7.4 Business Strategies 8.8 Silicon Biosystems, S.p.A. 8.8.1 Company Overview 8.8.2 Financial Overview 8.8.3 Product Portfolio 8.8.4 Business Strategies 8.8.5 Recent Developments
Browse the Circulating Tumor Cells Prognostic Technologies Market Research Report with complete TOC http://www.transparencymarketresearch.com/ctcs-prognostic-technologiesmarket.html
8.9 Vitatex, Inc. 8.9.1 Company Overview 8.9.2 Financial Overview 8.9.3 Product Portfolio 8.9.4 Business Strategies 8.10 Veridex, LLC 8.10.1 Company Overview 8.10.2 Financial Overview 8.10.3 Product Portfolio 8.10.4 Business Strategies
8.10.5 Recent Developments
About Us Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Contact: Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ Blog: https://tmrresearch.wordpress.com/